• Giuseppe Tridente


Bevacizumab (Avastin®, Genentec) is a recombinant humanized monoclonal IgG1k antibody specifically binding to soluble vascular endothelial growth factor (VEGF-A), and thus inhibiting its interaction with the respective receptors Flt-1 (VEGFR-1), KDR (VEGFR-2), and Ftl-4 (VEGF-3) located at the surface of endothelial cells.


Vascular Endothelial Growth Factor Epithelial Ovarian Cancer Cystoid Macular Edema mCRC Patient Vascular Endothelial Growth Factor Signaling 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

307171_1_En_10_MOESM1_ESM.xls (56 kb)
Supplementary material 1 (XLS 57 kb)


  1. 1.
    Avastin® (bevacizumab). Prescribing Information. Genentec May 2012Google Scholar
  2. 2.
    FDA Memorandum to the file BLA 125085 Avastin (bevacizumab) Dec 2010Google Scholar
  3. 3.
    Avastin® (Bevacizumab) Medicines Product Information. Genentech. (
  4. 4.
    Avastin® (Bevacizumab) BL 125085/169 Briefing Book Feb 2009Google Scholar
  5. 5.
    Avastin® (Bevacizumab) EPAR Product Information WC50002927 EMA Sept 2012Google Scholar
  6. 6.
    Avastin® (Bevacizumab) EMA Assessment Report WC 500029270 March 2008Google Scholar
  7. 7.
    Avastin® (Bevacizumab) EMA Refusal Assessment Report WC500075000 Jan 2010Google Scholar
  8. 8.
    Avastin® (Bevacizumab) BL 125085/191-192 Briefing Book July 2010Google Scholar
  9. 9.
    Avastin® (Bevacizumab) EMA WC500029271 Annex I Sept 2012Google Scholar
  10. 10.
    Ferrara N, Davys-Smith T (1997) The biology of vascular endothelial growth factor. Endocrine Rev 18:14–25Google Scholar
  11. 11.
    Konno H, Yamamoto M, Ohta M (2010) Recent concepts of angiogenic therapy. Surg Today 40:494–500PubMedCrossRefGoogle Scholar
  12. 12.
    Carmelier P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298–307 doi:  10.1038/nature10144 Google Scholar
  13. 13.
    Gressett SM, Shah SR (2009) Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 43:490–501PubMedCrossRefGoogle Scholar
  14. 14.
    Avastin® (Bevacizumab) FDA Primary Clinical Review STN 125085/0 Part 1, Feb 2004Google Scholar
  15. 15.
    Kabbinavar FF, Flynn PJ, Kozloff M et al (2012) Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study. Eur J Cancer 48:1126–1132PubMedCrossRefGoogle Scholar
  16. 16.
    Abu-Hejleh T, Mezhir JJ, Goodheart MJ et al (2012) Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers. Curr Oncol Rep 14:277–284PubMedCrossRefGoogle Scholar
  17. 17.
    Hayman SR, Leung N, Grande JP et al (2012) VEGF inhibition, hypertension and renal toxicity. Curr Oncol Rep 14:285–294PubMedCrossRefGoogle Scholar
  18. 18.
    Avastin® (Bevacizumab) BL 125085/191-Briefing Book June 2010Google Scholar
  19. 19.
    Troeltsch M, Woodlock T, Kriegelstein S et al (2012) Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw. J Can Dent Assoc 78(c85):1–7Google Scholar
  20. 20.
    Ang CS-P, Kemeny NE (2011) Bevacizumab in the management of colon cancer: a review. J Solid Tumors 1:120–131Google Scholar
  21. 21.
    van Cutsem E, Vervenne WL, Bennouna Y et al (2009) Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27:2231–2237PubMedCrossRefGoogle Scholar
  22. 22.
    Stopeck AT, Unger JM, Rimsza LM et al (2012) A phase II trial of standard dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non Hodgkin’s lymphoma: SWOG 0515. Blood doi: 10.1182/blood-2012-04-423079 (online pre-publication)
  23. 23.
    Sfakianos GP, Numnum TM, Halverson CB et al (2009) The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective study. Gynecol Oncol 114:424–426PubMedCrossRefGoogle Scholar
  24. 24.
    Randall LM, Monk BJ (2010) Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol 117:497–504PubMedCrossRefGoogle Scholar
  25. 25.
    Tanyi JL, McCann G, Hagemann AR et al (2011) Clinical predictors of bevacizumab-associated gastrointestinal perforation. Gynecol Oncol 120:464–469PubMedCrossRefGoogle Scholar
  26. 26.
    Schumcker C, Elken C, Agostini HT et al (2012) A safety meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PLoS ONE 7(8):e42701. doi: 10.1371/journal.pone.0042701 CrossRefGoogle Scholar
  27. 27.
    Campbell RJ, Gill SS, Bronskill SE et al (2012) Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study. BMJ. doi: 10.1136/bmj.e4203 Google Scholar
  28. 28.
    Ebos JML, Kerbel RS (2011) Angiogenic therapy: impact on invasion, disease progression and metastasis. Nat Rev Clin Oncol 8:210–221PubMedCrossRefGoogle Scholar
  29. 29.
    Jutley G, Shona OA, Cheong Leen R et al (2012) Response to ranibizumab following tachyphylaxis to bevacizumab in a patient with radiation maculopathy following stereotactic fractionated radiotherapy for optic nerve meningioma. Arch Ophthalmol 130:1466–1470Google Scholar

Copyright information

© Springer-Verlag Italia 2014

Authors and Affiliations

  1. 1.University of VeronaVeronaItaly

Personalised recommendations